1 – 10 of 27
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma
(
- Contribution to journal › Article
- 2022
-
Mark
Intratumoral administration of the antisecretory peptide AF16 cures murine gliomas and modulates macrophage functions
(
- Contribution to journal › Article
- 2020
-
Mark
Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas
(
- Contribution to journal › Article
- 2019
-
Mark
The effect of locally delivered cisplatin is dependent on an intact immune function in an experimental glioma model
(
- Contribution to journal › Article
- 2017
-
Mark
Establishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluation
(
- Contribution to journal › Article
- 2016
-
Mark
Preoperative systemic levels of VEGFA, IL-7, IL-17A, and TNF-β delineate two distinct groups of children with brain tumors
(
- Contribution to journal › Article
- 2015
-
Mark
A standardized and reproducible protocol for serum-free monolayer culturing of primary paediatric brain tumours to be utilized for therapeutic assays.
(
- Contribution to journal › Article
-
Mark
Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas.
(
- Contribution to journal › Article
- 2014
-
Mark
Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.
(
- Contribution to journal › Article
-
Mark
Immunizations with unmodified tumor cells and simultaneous COX-2 inhibition eradicate malignant rat brain tumors and induce a long-lasting CD8(+) T cell memory.
(
- Contribution to journal › Article